Press Releases

If you want to subscribe to our press releases please go to the Cision site where it is possible to subscribe.

Note: After January 21, 2020, all press releases are published in English as original language.

ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development

01-12-2023 Regulatory pressrelease

Hørsholm, Denmark, 1 December 2023 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces the award of a Horizon Europe grant amounting to 8 million EUR, approximately 90 million SEK, to the VICI-Disease consortium, of which 53% is direct contribution for ExpreS2ion’s part of the project costs. The aim is to obtain…

ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report

27-11-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 27 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that ExpreS2ion CEO Bent Frandsen participated in a Finwire interview, CFO Keith Alexander participated in the Økonomisk Ugebrev Life Science Investor Conference on 22 November, and Analysguiden has published a research report on ExpreS2ion in November.

ExpreS2ion announces financial results for the third quarter 2023

16-11-2023 Regulatory pressrelease

Hørsholm, Denmark, 16 November 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023

09-11-2023 Regulatory pressrelease

Helsingborg, Sweden, 9 November 2023 - The extraordinary general meeting ("EGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today, 9 November 2023, in Helsingborg, Sweden.

ExpreS2ion to participate in upcoming events

03-11-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 3 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the Conference on Vaccines R&D (6-8 November), BIO-EUROPE (6-8 November) and the Vaccines Summit (13-15 November).

Background and rationale for the proposed incentive program 2023/2026

25-10-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 25 October 2023 - With reference to Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (Press release as of Monday 23 October 2023) the board of directors hereby provides further details to the background and rationale for the proposed incentive program 2023/2026.

Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB

23-10-2023 Regulatory pressrelease

N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729 (the "Company"), are hereby convened to the Extraordinary General Meeting to be held on 9 November 2023 at…

Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB

23-10-2023 Regulatory pressrelease

Aktieägarna i ExpreS2ion Biotech Holding AB, org.nr 559033-3729 ("Bolaget"), kallas härmed till extra bolagsstämma den 9 november 2023 klockan 10:00 på Mindpark, Bredgatan 11, i Helsingborg. Inpassering och registrering till stämman startar klockan 09:30.

ExpreS2ion to participate in upcoming events

12-10-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 12 October 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress Europe (16-19 October) and the Conference on Vaccines Research & Development (6-8 November).

ExpreS2ion announces changes to leadership team

27-09-2023 Regulatory pressrelease

Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical Development, are stepping down from their positions in the Company following…

Warrants of series TO 8 were exercised to approximately 18.5 percent and ExpreS2ion receives approximately SEK 3.4 million

25-09-2023 Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies is today, 18 September 2023

18-09-2023 Regulatory pressrelease

ExpreS2ion’s Board, CEO and CFO commit to full exercise of their series TO 8 warrants

13-09-2023 Regulatory pressrelease

ExpreS2ion announces the start of the exercise period for warrants of series TO 8

07-09-2023 Regulatory pressrelease

ExpreS2ion publishes video presentation

05-09-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 05 September 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents an update on development of ExpreS2ion’s business model, pipeline assets, recent developments, TO 8 warrant program and advancement towards key catalysts is now available on…

ExpreS2ion announces TO 8 warrant exercise price and start of exercise period

04-09-2023 Regulatory pressrelease

Phase III secondary endpoint data announced for the COVID-19 booster vaccine candidate

31-08-2023 Regulatory pressrelease

Hørsholm, Denmark, 31 August 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for ABNCoV2, a capsid virus-like particle (cVLP) based non-adjuvanted COVID-19 booster vaccine. Bavarian Nordic reports that the booster study did not successfully meet its secondary endpoint, in which the…

Correction: ExpreS2ion announces financial results for the second quarter 2023

17-08-2023 Regulatory pressrelease

Hørsholm, Denmark, 17 August 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report. This press release is a correction to the press release made earlier this morning, which did not…

ExpreS2ion announces financial results for the second quarter 2023

17-08-2023 Regulatory pressrelease

ExpreS2ion evaluates strategic options for its breast cancer vaccine candidate

17-08-2023 Regulatory pressrelease

Hørsholm, Denmark, 17 August 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the Board has decided to assess strategic options for the ES2B-C001 breast cancer project, aimed at conserving capital resources to further advance the company’s exploratory vaccine pipeline and technology platforms.

Phase III topline results announced for the COVID-19 booster vaccine candidate

27-06-2023 Regulatory pressrelease

Hørsholm, Denmark, 27 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for ABNCoV2, a capsid virus-like particle (cVLP) based non-adjuvanted COVID-19 booster vaccine. Bavarian Nordic reports that the booster study successfully met its primary endpoint, demonstrating non-inferiority to mRNA-vaccine, and…

12-month durability data announced for ABNCoV2 Phase II clinical trial

16-06-2023 Regulatory pressrelease

Hørsholm, Denmark, 16 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase II clinical trial for ABNCoV2, a capsid virus-like particle (cVLP) based non-adjuvanted COVID-19 booster vaccine. Today Bavarian Nordic announced that the results of a 12-month follow-up analysis from a subset of subjects…

ExpreS2ion to participate in upcoming events

01-06-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 1 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the 2023 BIO International Convention (5-8 June), Aktiespararna’s Small-Cap Day (13 June), and the 2023 Virus-Like Particle & Nano-Particle Vaccines Conference (27-29 June).

Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 24 May 2023

24-05-2023 Regulatory pressrelease

Helsingborg, Sweden, 24 May 2023 – The annual general meeting 2023 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today, 24 May 2023, in Helsinborg, Sweden.

ExpreS2ion announces financial results for the first quarter 2023

16-05-2023 Regulatory pressrelease

Hørsholm, Denmark, 16 May 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion - Annual report for 2022 published

02-05-2023 Regulatory pressrelease

Hørsholm, Denmark, 2 May 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2022 is published. The annual report is available as an attachment and on ExpreS2ion's website at the following address (https://investor.expres2ionbio.com/reports/).

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB

24-04-2023 Regulatory pressrelease

N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729 (the "Company"), are hereby convened to the Annual General Meeting to be held on 24 May 2023 at…

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

21-04-2023 Regulatory pressrelease

ExpreS2ion announces poster presentation on ES2B-C001 at the AACR Annual Meeting 2023

18-04-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 18 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company through its research collaboration partners at University of Bologna presented a poster on ES2B-C001, our unique HER2-VLP breast cancer vaccine candidate, at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19,…

ExpreS2ion announces final outcome of its rights issue

14-04-2023 Regulatory pressrelease

Rights issue subscription period ending 12 April 2023; subscription possible via form

11-04-2023 Regulatory pressrelease

ExpreS2ion publishes video presentation

11-04-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 11 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents provides an update on development of ExpreS2ion’s leading pipeline assets, potential markets and the 2023 Rights Issue, is now available on the company’s website.

ExpreS2ion to participate in upcoming events

28-03-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 27 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include Swiss Nordic Bio (30 March), a Rights Issue Q&A (31 March), the AACR Annual Meeting (14-19 April) and the Økonomisk Ugebrev Life Science…

ExpreS2ion publishes prospectus in connection with its rights issue of units

27-03-2023 Regulatory pressrelease

Hørsholm, Denmark, 27 March 2023 – On 3 March 2023, the Board of Directors of Expres2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) resolved, conditional upon approval from the extraordinary general meeting, to carry out a new issue of units consisting of shares and warrants of series TO8 (“Units”) with preferential rights for the Company’s…

Bulletin from ExpreS2ion's extraordinary general meeting on 23 March 2023

23-03-2023 Regulatory pressrelease

Helsingborg, Sweden, 23 March 2023 – ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “Company”) extraordinary general meeting took place today. The extraordinary general meeting resolved to approve the Board of Directors' resolution to carry out a new issue of units consisting of shares and warrants of series TO 8 ("Units") with preferential rights for the…

Pareto and Analysguiden publish research reports

16-03-2023 Non-regulatory pressrelease

Hørsholm, Denmark, 16 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in March. Both sponsored research analysts commented on the recently announced rights issue and MucoVax collaboration. Analysguiden reduced its price target to SEK 12 per share, primarily…

ExpreS2ion announces formation of Infectious Diseases Scientific Advisory Board

09-03-2023 Non-regulatory pressrelease

Hørsholm, Denmark, March 9, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Infectious Diseases Scientific Advisory Board (ISAB). The four initial members of the ExpreS2ion ISAB bring a depth of knowledge in infectious diseases, clinical trials and preventive vaccines, and will contribute to the development of…

Notice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB

03-03-2023 Regulatory pressrelease

N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. Shareholders of ExpreS[2]ion Biotech Holding AB are hereby invited to an Extraordinary General Meeting on 23 March 2023 at 10:00 CET at Mindpark, Bredgatan 11, 252 25 Helsingborg,…

ExpreS2ion announces a rights issue of units of approximately SEK 102.4 million

03-03-2023 Regulatory pressrelease

ExpreS2ion announces grant award for the development of new platforms for universal mucosal vaccines

03-03-2023 Regulatory pressrelease

Hørsholm, Denmark, March 3, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the MucoVax consortium has been awarded an Innovation Fund Denmark (IFD) Grand Solutions grant for the development of new platforms for universal mucosal vaccines in a 5-year research project in a collaboration between ExpreS2ion and University of Copenhagen.…

ExpreS2ion provides update on ABNCoV2 Phase III clinical trial

15-02-2023 Regulatory pressrelease

Hørsholm, Denmark, February 15, 2023– ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine. Today Bavarian Nordic announced that the top-line results are now anticipated around mid-2023 due to longer than expected recruitment…

ExpreS2ion will present fourth quarter and full-year 2022 results

13-02-2023 Non-regulatory pressrelease

Hørsholm, Denmark, February 13, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") is pleased to announce that it will present fourth quarter and full-year 2022 results via webcast on February 15th, 2023, at 14:30 CET.

ExpreS2ion announces financial results for the fourth quarter and full-year 2022

09-02-2023 Regulatory pressrelease

Hørsholm, Denmark, February 9, 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2

20-01-2023 Non-regulatory pressrelease

Hørsholm, Denmark, January 20, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal The Lancet Microbe published an article about the COVID-19 vaccine candidate ABNCoV2 titled “First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2” co-authored by…

ExpreS2ion will participate in the 41st annual J.P. Morgan Healthcare Conference and present at Biotech Showcase

03-01-2023 Non-regulatory pressrelease

Hørsholm, Denmark, January 3, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce that it will present at the Biotech Showcase and will participate in the J.P. Morgan Healthcare Conference from January 9 to 12, 2023.

ExpreS2ion further strengthens leadership team with appointment of Chief Scientific Officer

03-01-2023 Regulatory pressrelease

Hørsholm, Denmark, January 3, 2023 – ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion” or the “Company”) hereby announces the appointment of Dr. Farshad Guirakhoo as the Company’s new Chief Scientific Officer (CSO). Dr. Guirakhoo has more than 30 years of broad translational research experience in the vaccine development field, and will be responsible for directing the development…

ExpreS2ion and Evaxion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

06-12-2022 Regulatory pressrelease

Hørsholm, Denmark, December 6, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the company has signed a Vaccine Discovery Collaboration Agreement with Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”) for the joint development of a novel cytomegalovirus (CMV) vaccine candidate. The collaboration will combine ExpreS2ion’s ExpreS2 platform and resources for vaccine…

Pareto and Analysguiden publish research reports with SEK 25 per share price targets and ExpreS2ion publishes third quarter financial report video presentation

18-11-2022 Non-regulatory pressrelease

Hørsholm, Denmark, November 18, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in November. Pareto reiterated its SEK 25 price target while Analysguiden reduced its price target to SEK 25 per share from SEK 30 per share. Furthermore, a…

ExpreS2ion announces financial results for the third quarter 2022

17-11-2022 Regulatory pressrelease

Hørsholm, Denmark, November 17, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion will participate in key industry and investor events

15-11-2022 Non-regulatory pressrelease

Hørsholm, Denmark, November 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PEGS Europe Protein & Antibody Engineering Summit (November 14-16), the presentation of Q3 2022 results (November 17), and the BioStock Life Science Summit…

ExpreS2ion Announces Formation of Oncology Scientific Advisory Board

03-11-2022 Non-regulatory pressrelease

Hørsholm, Denmark, November 3, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development…

Scientific article published about ExpreS2ion’s human candidate HER-2 virus-like particle vaccine, ES2B-C001

24-10-2022 Non-regulatory pressrelease

Hørsholm, Denmark, October 24, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal Biomedicines published an article about the breast cancer vaccine candidate ES2B-C001 titled “Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine”.

Durable antibody response reported for the ABNCoV2 COVID-19 vaccine six months after vaccination in the Phase II clinical trial

17-10-2022 Regulatory pressrelease

Hørsholm, Denmark, October 17, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that follow-up results from Bavarian Nordic’s Phase II clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine show that antibody titers remained high at levels associated with greater than 90% efficacy six months after vaccination…

Phase III trial for the ABNCoV2 COVID-19 vaccine to start inclusion of Danish subjects

07-10-2022 Non-regulatory pressrelease

Hørsholm, Denmark, October 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s ongoing Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine, which started to include subjects in the United States in September, will also start to include subjects in Denmark…

Board member Allan Rosetzsky resigns

06-10-2022 Regulatory pressrelease

Hørsholm, Denmark, October 6, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that Allan Rosetzsky, with immediate effect, has decided to resign from ExpreS2ion’s board of directors. Hereafter the board of directors will consist of Martin Roland Jensen (Chair), Jakob Knudsen, Karin Garre, and Sara Sande.

ExpreS2ion publishes investor video presentation

27-09-2022 Non-regulatory pressrelease

Hørsholm, Denmark, September 27, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at Aktiedagen Lund in which he presents provides an update on ExpreS2ion’s powerful technology platform for vaccine development, pipeline projects, and key financial figures, is now available on the…

Pareto publishes research report setting price target of SEK 25 per share as new analyst assumes coverage

22-09-2022 Non-regulatory pressrelease

Hørsholm, Denmark, September 22, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company.

ExpreS2ion will participate in key industry and investor events

20-09-2022 Non-regulatory pressrelease

Hørsholm, Denmark, September 20, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28), and Aktiedagen Lund (September 26).

ExpreS2ion announces full exercise of 2019 warrant program

07-09-2022 Regulatory pressrelease

Hørsholm, Denmark, September 7, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 308,268 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 1,482,769. The exercise has increased the number of shares by 308,268 from 37,298,528 to 37,606,796. All 612,084 TO2 warrants have now been exercised,…

First subject vaccinated in COVID-19 Phase III clinical trial for ABNCoV2 as a booster vaccine

02-09-2022 Regulatory pressrelease

Hørsholm, Denmark, September 2, 2022 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion") announces that a Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic, including the vaccination of the first subject. The trial aims to demonstrate non-inferiority of ABNCoV2 as…

ExpreS2ion announces financial results for the second quarter 2022

18-08-2022 Regulatory pressrelease

Hørsholm, Denmark, August 18, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion will participate in key industry and investor events

15-08-2022 Non-regulatory pressrelease

Hørsholm, Denmark, August 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include a presentation of Q2 2022 results (August 18), the LSX Nordic Investor Conference (September 6-7), and PIVAC-22, a forum covering the most recent…

ExpreS2ion announces exercise of 2019 warrant program, second tranche of three

10-08-2022 Regulatory pressrelease

Hørsholm, Denmark, August 10, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 136,422 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 656,190. The exercise has increased the number of shares by 136,422 from 37,162,106 to 37,298,528.

ExpreS2ion announces exercise of 2019 warrant program

11-07-2022 Non-regulatory pressrelease

Hørsholm, Denmark, July 11, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 167,394 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 805,165. The exercise has increased the number of shares by 167,394 from 36,994,712 to 37,162,106.

Updated Phase III trial for the ABNCoV2 COVID-19 vaccine to include a licensed mRNA vaccine

16-06-2022 Regulatory pressrelease

Hørsholm, Denmark, June 16, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s upcoming Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been redesigned due to a licensed mRNA vaccine now being available as a comparator vaccine. This enables the design…

Analysguiden publishes research report setting price target of SEK 30 with an optimistic fair value of SEK 60

13-06-2022 Non-regulatory pressrelease

Hørsholm, Denmark, June 13, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast…

ExpreS2ion publishes video presentation

01-06-2022 Non-regulatory pressrelease

Hørsholm, Denmark, June 1, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CFO Keith Alexander and Vice President of Preclinical Development Mette Thorn in which they provide an update on ExpreS2ion’s breast cancer vaccine candidate, ES2B-C001, is now available on the company’s website.

ExpreS2ion announces financial results for the first quarter 2022

31-05-2022 Regulatory pressrelease

Hørsholm, Denmark, May 31, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Announcement from ExpreS2ion's annual general meeting

25-05-2022 Regulatory pressrelease

The annual general meeting 2022 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 25 May 2022. The AGM was carried out through advance voting (postal voting) pursuant to temporary legislation and the following resolutions were passed by the meeting.

Scientific publication by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis

25-05-2022 Non-regulatory pressrelease

Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the scientific journal Vaccines published an article authored by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis.

Additional positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

25-05-2022 Regulatory pressrelease

Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated additional positive proof-of-concept also in a metastatic outgrowth therapeutic tumor mice model. These data support the already established preclinical proof-of-concept results announced in December 2021 (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-positive-topline-results-for-its-her2-cvlp-breast-cancer-vaccine--demonstrating,c3476944) and…

ExpreS2ion will participate in key industry and investor events

24-05-2022 Non-regulatory pressrelease

Hørsholm, Denmark, May 24, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include an Oncology webinar (May 31) and presentation of Q1 2022 results (June 9), both hosted by H.C. Andersen Capital, the ECI Vaccine Technology…

Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS

09-05-2022 Non-regulatory pressrelease

Hørsholm, Denmark, May 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.

ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SEK 73 million

05-05-2022 Regulatory pressrelease

Positive Omicron data from the COVID-19 Phase II trial reported for the ABNCoV2 vaccine

05-05-2022 Regulatory pressrelease

Hørsholm, Denmark, May 5, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been reported from the Phase II clinical trial conducted by Bavarian Nordic. The new study data demonstrates a significant boost to…

ExpreS2ion - Annual report for 2021 published

04-05-2022 Regulatory pressrelease

Hørsholm, Denmark, May 04, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2021 is published. The annual report is available as an attachment and on ExpreS2ion's website at the following address (https://investor.expres2ionbio.com/reports/).

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

25-04-2022 Regulatory pressrelease

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 25 May 2022.

ExpreS2ion publishes video presentation

20-04-2022 Non-regulatory pressrelease

Hørsholm, Denmark, April 20, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents provides an update on ExpreS2ion’s powerful platform for vaccine development, updates on the pipeline and progress towards key catalysts and the 2022 Rights Issue, is…

Frontiers in Immunology publishes article about ABNCoV2

19-04-2022 Non-regulatory pressrelease

Hørsholm, Denmark, April 19, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Immunology published an article about the high level of antibodies induced by the ABNCoV2 COVID-19 vaccine in non-human primates.

ExpreS2ion publishes prospectus in connection with fully guaranteed rights issue of approximately SEK 73 million

13-04-2022 Regulatory pressrelease

Pareto Securities publishes research report revising price target to SEK 86

08-04-2022 Non-regulatory pressrelease

Hørsholm, Denmark, April 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their analysis of ExpreS2ion following the announcement that the Company will be conducting a Rights Issue. Pareto reiterated its ‘buy’ rating and reduced its target price to SEK 86 per share after incorporating the…

ExpreS2ion will participate in key industry and investor events

07-04-2022 Non-regulatory pressrelease

Hørsholm, Denmark, April 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress (April 18-21), a Q&A session covering the 2022 Rights Issue (April 25), Økonomisk Ugebrev Life Science Investor Conference (April…

ExpreS2ion announces a fully guaranteed rights issue of approximately SEK 73 million

06-04-2022 Regulatory pressrelease

AdaptVac wins EY’s 2021 Entrepreneur of the Year Award in the Danish Life Sciences category

25-03-2022 Non-regulatory pressrelease

Hørsholm, Denmark, March 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that 34%-owned associated company AdaptVac ApS has won EY’s prestigious Entrepreneur of the Year 2021 award in the Life Sciences category for Denmark.

ExpreS2ion publishes video from company presentation at Aktiespararna’s Aktiedagen

15-03-2022 Non-regulatory pressrelease

Hørsholm, Denmark, March 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the Aktiespararna Aktiedagen investor event on March 14, 2022 is now available on the company’s website.

ExpreS2ion will participate at key industry and investor events in March 2022

09-03-2022 Non-regulatory pressrelease

Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March. These include Aktiespararna’s Aktiedagen (March 14), the Swiss Nordic Bio event (March 23), and BIO-Europe Spring (March 28-31).

Analysguiden publishes research report setting new price target of SEK 39 with an optimistic fair value of at least SEK 80

09-03-2022 Non-regulatory pressrelease

Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results, the release of additional positive Phase II COVID-19 results, and the announcement of the plan to initiate a regulatory validated Phase…

Pareto publishes research report increasing price target to SEK 99

01-03-2022 Non-regulatory pressrelease

Hørsholm, Denmark, March 1, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results and the release of additional positive Phase II COVID-19 results for the ABNCoV2 vaccine. Pareto upheld its ‘buy’ rating and…

Additional positive Phase II COVID-19 results presented for the ABNCoV2 vaccine

28-02-2022 Regulatory pressrelease

Hørsholm, Denmark, February 28, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been presented from the Phase II clinical trial conducted by Bavarian Nordic. The full study data confirms that existing levels of…

ExpreS2ion announces financial results for the fourth quarter and full-year 2021

24-02-2022 Regulatory pressrelease

Hørsholm, Denmark, February 24, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full year financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion provides an update on its novel breast cancer vaccine candidate ES2B-C001

08-02-2022 Regulatory pressrelease

Hørsholm, Denmark, February 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) announces constructive feedback from its scientific advice meeting pertaining to the therapeutic breast cancer vaccine candidate, ES2B-C001, with the Danish Medicines Agency (“DKMA”). Based on this feedback, ExpreS2ion plans to conduct an additional preclinical safety study in…

ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

04-01-2022 Regulatory pressrelease

Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important…

ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept

22-12-2021 Regulatory pressrelease

Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively…

ExpreS2ion appoints new Chief Medical Officer

21-12-2021 Regulatory pressrelease

Hørsholm, Denmark, December 21, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces the appointment of Dr. Mattis F. Ranthe as the Company’s new Chief Medical Officer (CMO). Dr. Ranthe brings a decade of broad clinical experience, and he will be responsible for ensuring the progression of ExpreS2ion’s development pipeline activities, including…

Pareto Securities and Analysguiden publish research reports; Pareto increases price target to SEK 79

09-12-2021 Non-regulatory pressrelease

Hørsholm, Denmark, December 9, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in December, following the publication of initial results for the phase II testing of ABNCoV2. Pareto reiterated its ‘buy’ rating and increased its target price SEK…

Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine

05-12-2021 Regulatory pressrelease

Hørsholm, Denmark, December 5, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. The existing levels of SARS-CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious…

ExpreS2ion will participate in key investor events in December 2021

29-11-2021 Non-regulatory pressrelease

Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.

Pareto Securities and Analysguiden publish research reports; Analysguiden increases price target to SEK 60

19-11-2021 Non-regulatory pressrelease

Hørsholm, Denmark, November 19, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in November, following the publication of Q3 2021 results. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has…

ExpreS2ion announces financial results for the third quarter of 2021

15-11-2021 Regulatory pressrelease

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion’s Interim Report for Q3 2021 will be published today

15-11-2021 Regulatory pressrelease

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Interim Report for Q3 2021 will be published today, as the report is finalized earlier than planned. The previous date for publication of the report was Thursday, November 18[th], 2021.